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The human adult heart lacks a robust endogenous repair mechanism to fully restore cardiac function after insult; thus, the ability
to regenerate and repair the injured myocardium remains a top priority in treating heart failure. The ability to efficiently generate
a large number of functioning cardiomyocytes capable of functional integration within the injured heart has been difficult.
However, the ability to directly convert fibroblasts into cardiomyocyte-like cells both in vitro and in vivo offers great promise
in overcoming this problem. In this review, we describe the insights and progress that have been gained from the
investigation of direct cardiac reprogramming. We focus on the use of key transcription factors and cardiogenic genes as well
as on the use of other biological molecules such as small molecules, cytokines, noncoding RNAs, and epigenetic modifiers to
improve the efficiency of cardiac reprogramming. Finally, we discuss the development of safer reprogramming approaches for
future clinical application.
1. Introduction
Heart failure (HF), the leading cause of death and hospitali-
zations worldwide, results from a myriad of cardiovascular
diseases that lead to the death or dysfunction of cardio-
myocytes. With a prevalence of 38 million people world-
wide, it places a significant financial burden on health
care systems, with an estimated $30 billion of annual
spending in just the United States alone [1, 2]. Despite
recent advances in the care and management of HF
patients, the prognosis of advanced HF remains dismal at
50% survival at 5 years, a rate often lower than that of
many cancers [3, 4]. Considering that the pathophysiology
of HF involves death or dysfunction of the cardiac myocyte,
new therapeutic strategies for heart regeneration may offer
hope to this intractable disease.
The human adult heart lacks endogenous repair mech-
anisms to fully restore cardiac function after an insult;
thus, the ability to regenerate and repair the injured
myocardium remains a top priority in treating HF. However,
the ability to efficiently generate a large number of function-
ing cardiomyocytes capable of functional integration within
the injured heart has remained an obstacle. Current cell ther-
apies are focused on three main approaches: (1) induction of
endogenous cardiomyocytes to undergo proliferation and
repopulate the damaged myocardium, (2) transplantation
of cardiovascular progenitor cells (CPCs) or cardiomyocytes
generated through the differentiation of pluripotent stem
cells, and (3) direct reprogramming of somatic cells to
cardiomyocytes or expandable CPCs without transitioning
through a pluripotent intermediate. This review is focused
on the last approach. Direct reprogramming was first
reported in 1987 when a single cDNA encoding MyoD was
transfected into fibroblasts converting them into muscle
myoblasts [5]. A few years later, MyoD was identified as the
master regulator gene for skeletal muscle development [6].
The ability to directly reprogram adult cells to a desirable
fate demonstrates an immense potential of this powerful
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tool for tissue regeneration and replacement. Since the
identification of MyoD, there has been extensive focus
on the identification of master regulator(s) for other cell
lineages and this search has led to the successful conversion
of mature cells into other cells types including myoblasts,
neurons, hepatocytes, intestinal cells, blood progenitor cells,
and cardiomyocytes [5, 7–11].
In this review, we describe the insights and progress
that have been gained from the investigation of direct
cardiac reprogramming, with a focus on the use of key
transcription factors and other cardiogenic genes. Further-
more, we discuss the use of other biologics and small mol-
ecules to improve the efficiency of cardiac reprogramming
and the development of safe reprogramming approaches
for clinical application.
2. Reprogramming of Somatic
Cells to Cardiomyocyte-Like Cells by
Overexpression of Key Cardiac
Transcription Factors
Direct reprogramming of fibroblasts into cardiomyocyte-like
cells was first reported in 2010 using viral overexpression of
three important cardiac developmental transcription factors
(TFs), Gata4, Mef2c, and Tbx5 (GMT) in mouse cardiac
and tail-tip fibroblasts [11]. Ieda et al. used an iterative
screening approach in which 14 factors were removed
one by one to identify those that were dispensable for
direct reprogramming. This process ultimately identified
GMT as the factors sufficient to induce conversion of
fibroblasts to cardiomyocyte-like cells without transition-
ing through a progenitor state. TBX5 is an important T-
box TF involved in early cardiac development that directs
formation of the primary heart field through a coordinated
but yet complex interaction with other TFs [12]. One such
interaction is with GATA4, a member of the GATA family
zinc-finger TFs, which modifies the chromatin structure
allowing other TFs such as NKX2–5 to bind to their targets
and fully activate the cardiac transcriptional program [13].
MEF2c, a MADS box transcription enhancer factor, is
important for the formation of the secondary heart field
through its interaction with other cardiac TFs [14]. After
the establishment of GMT as the core TFs for direct car-
diac reprograming, much of the focus transitioned to
improving the reprogramming efficiency and/or the func-
tion of the induced cardiomyocyte-like cells (iCMs)
through addition of other important cardiac TFs to
GMT. This was mainly due to the poor efficiency of
reprogramming, reported to be 4.8% cardiac troponin T
+ (cTnT+) cells in the original paper. Additionally, it
was soon noted that GMT alone was insufficient to con-
vert human fibroblasts to iCMs.
One of the first TFs added to GMT was the bHLH TF
HAND2 (referred to as GMHT). In cardiac development,
HAND2 plays an important role in the formation of the
ventricular chambers through interaction with GATA4 and
NKX2–5 [15]. GMHT treatment of mouse embryonic
fibroblasts (MEFs) resulted in iCMs expressing low levels of
sarcomeric proteins and displayed immature characteristics
of the main cardiac cell types (atrial, ventricular, and pace-
maker) [16]. In an effort to increase transcriptional activity
of GMHT, the transactivation domain of MyoD was fused
to each G, M, H, or T and overexpressed in mouse fibro-
blasts. When MyoD was fused to Mef2c, a 15-fold increase
in reprogramming efficiency was observed [17]. Other TFs
that are essential during cardiovascular development have
also been studied for direct reprogramming. NKX2–5, a
homeobox TF critical for normal heart morphogenesis,
was overexpressed in mouse fibroblasts in addition to
GMHT. This combination resulted in a more than 50-fold
increase in the efficiency of cardiac reprogramming
compared to GMT alone and produced iCMs with mature
cardiomyocyte marker expression, robust calcium oscilla-
tion, and spontaneous beating [18].
Additionally, an alternative screening approach that
surveyed triplet combinations of 10 important cardiac TFs
revealed that Tbx5, Mef2c, and Myocd, a developmental
regulator of cardiomyocytes and smooth muscle cells, were
able to induce a more complete cardiac phenotype than
GMT in mouse fibroblasts [19]. Likewise, a combinatorial
screen of 10 transcription factors added to GMT in MEFs
identified a combination of cocktails that resulted in
successful reprogramming. GMT plus Myocd and Srf, a
TF important in mesoderm formation, or GMT plus
Myocd, Srf, Mesp1, another mesoderm-inducing TF, and
Smarcd3, a chromatin structure-altering protein, enhanced
reprogramming and the expression of cardiac sarcomeric
proteins over GMT alone [20].
Despite the successes of TF overexpression to reprogram
murine cells, similar approaches to reprogram human
somatic cells have been more difficult to achieve. Only a
few studies have reported successful reprogramming of
human cells to iCMs using TFs alone. The first of these
studies reported a combination of the E26 transformation-
specific (ETS) TF family member ETS2 and MESP1 proteins
to induce reprogramming of human dermal fibroblasts to
cardiac progenitors [21]. Another study using GMT with
MESP1 and MYOCD in human cardiac and dermal fibro-
blasts was sufficient to induce expression of multiple
cardiac-specific proteins, increase a broad range of cardiac
genes, and exhibit spontaneous calcium transients [22]. The
third report showed that expressing GMT along with ESSRG
(a transcriptional activator), MESP1, MYOCD, and ZFPM2
(a modulator of GATA proteins) in human fetal cardiac
fibroblasts and neonatal skin fibroblasts enhanced cardiac
reprogramming, sarcomere formation, calcium transients,
and action potentials [23]. Results of TF-based reprogram-
ming are summarized in Table 1.
3. Improving the Efficiency of Direct
Reprogramming with Biological Molecules
Despite the successes of direct reprogramming using
forced expression of cardiac TFs, the efficiency remains
low. The initial report on direct conversion of fibroblasts
to cardiomyocyte-like cells noted an efficiency of 4.8%.
In an effort to improve reprogramming efficiency, many
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methods have been developed using additional molecules.
These additives can be classified into three major categories:
inhibitors/cytokines, noncoding RNAs, and epigenetic mod-
ifiers. A summary of these reprogramming experiments is
presented in Table 2.
3.1. Inhibitors/Cytokines. A potential approach to improving
reprogramming is to inhibit the endogenous signaling
pathways and gene programs that maintain the distinct prop-
erties of fibroblasts. One of the major signaling pathways
active in fibroblasts is the transforming growth factor-
(TGF-) β pathway. TGF-β has diverse and pleotropic effects
through its activation and signaling. The downstream effect
of the TGF-β signaling pathway involves phosphorylation
of receptor-regulated SMADs that ultimately activate TFs
that participate in the regulation of target gene expressions,
many of which are critical in fibroblast activation and
proliferation. Since inhibition of TGF-β has been shown to
increase mouse embryonic stem cell differentiation to
cardiomyocytes [24, 25], it was hypothesized that TGF-β
inhibition could improve reprogramming. The TGF-β
inhibitors SB431542 and A83-01 have been added to various
reprogramming combinations and have shown an increase in
reprogramming efficiency. SB431542 is a selective and potent
inhibitor of the TGF-β pathway through suppression of the
activin A receptors ALK5, ALK4, and ALK7. A83-01 is also
a selective inhibitor of ALK5, ALK4, and ALK7 but is more
potent than SB431542 in its inhibition and effectively blocks
phosphorylation of Smad2. When SB431542 was combined
with GMHT, a 5-fold increase in reprogramming efficiency
was observed in both MEFs and mouse adult cardiac
fibroblasts [26]. Likewise, we observed an increase in
Table 1: Summary of transcription factor direct cardiac reprogramming results.
Reprogramming factors Mouse/human In vitro/in vivo Reported efficiency Analysis method Reference
GMT Mouse Both
4.8% cTnT+ (in vitro)
17% αMHC+ (in vitro)
FC [11, 54]
GMHT Mouse Both 27.6% cTnT+ (in vitro) FC [16, 53]
GMHT, MyoD transactivation domain Mouse In vitro 19% cTnT+ IF [17]
GMHT, Nkx2–5 Mouse In vitro 1.6% GCaMP+ IF [18]
MT, Myocd Mouse In vitro 12% cTnT+ FC [19]
GMT, Myocd, Srf, Mesp1, Smarcd3 Mouse In vitro 2.4% αMHC+ FC [20]
ETS2, MESP1 Human In vitro 13.7% αMHC+ FC [21]
GMT, MESP1, MYOCD Human In vitro 5.9% cTnT+ FC [22]
GMT, ESSRG, MESP1, MYOCD, ZFPM2 Human In vitro 18.1% αMHC+ FC [23]
FC: flow cytometry; IF: immunofluorescence.
Table 2: Summary of direct cardiac reprogramming results.
Reprogramming factors Mouse/human In vitro/in vivo Reported efficiency Analysis method Reference
GMHT, SB431542 Mouse In vitro 9.3% GCaMP+ IF [26]
GMHT, DAPT Mouse In vitro 38% cTnT+ IF [28]
GM(H)T, FGF2, FGF10, VEGF Mouse In vitro 2.9% cTnT+ FC [32]
miRNA-1, miRNA-133, miRNA-208,
miRNA-499
Mouse In vivo 12% tdTomato+cTnT+ IHC [36]
miRNA-1, miRNA-133, miRNA-208,
miRNA-499, JAK inhibitor I
Mouse Both 28% αMHC+ (in vitro) FC [30]
GMT, Mesp1, Myocd, miRNA-133
Mouse
Human
In vitro
12.9% cTnT+
27.8% cTnT+
FC [35]
GHT, MYOCD, miRNA-1, miRNA-133 Human In vitro 34.1% cTnT+ FC [37]
GMHT, miRNA-1, miRNA-133,
miRNA-208, miRNA-499, Y-27632, A83-01
Mouse In vitro 60% cTnT+ IF [29]
GMT, miRNA-590
Human
Porcine
In vitro 4.6% cTnT+ FC [39]
Ascorbic acid, RepSox, forskolin,
valproic acid, CHIR99021
Mouse In vitro 9% αMHC+ FC [60]
CHIR99021, BIX01294, A83-01, AS8351, SC1,
OAC2, Y27632, SU16F, JNJ10198409
Human In vitro 6.6% cTnT+ FC [61]
FC: flow cytometry; IF: immunofluorescence; IHC: immunohistochemistry.
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reprogramming efficiency, with frequent areas of spontane-
ous contraction and enhanced expression of cardiac
contractile proteins when we reprogrammed MEFs with
GMT and A83-01 cells (Figure 1). Furthermore, when GMT
and SB431542 were combined with WNT inhibition by
XAV939, reprogramming efficiency was increased 8-fold
in cardiac fibroblasts with respect to GMT alone [27]. In
addition to the TGF-β pathway, other profibrotic and intra-
cellular signaling pathways such as the Rho-associated
kinase, JAK/STAT, Notch and Akt pathways have been
targeted to improve reprogramming [28–31].
The utility of other molecules to enhance cardiac
reprogramming has been inspired by using cytokines
and/or modulators that are critical in mammalian cardiac
development, many of which are commonly used in the
differentiation of cardiomyocytes from pluripotent stem
cells. Fibroblast growth factor-2 (FGF2), FGF10, and vascular
endothelial growth factor (VEGF) in combination with GMT
or GMHT in MEFs and mouse tail-tip fibroblasts showed an
increase in the number of iCMs that spontaneously con-
tract [32]. These approaches also accelerated maturation
of iCMs in vitro, and thus, the activation of the important
developmental pathway during reprogramming warrants
further research.
3.2. Noncoding RNAs. MicroRNAs (miRNAs) are small
noncoding RNAs that induce degradation or inhibit trans-
lation of target mRNAs. miRNAs are an attractive additive
to reprogramming since they play important roles in the
posttranscriptional regulation of cardiac gene expression
and have critical function in almost every stage of heart
development. miRNA-1, miRNA-133, miRNA-208, and
miRNA-499 have been shown to be cardiac- and muscle-
specific and play important roles in cardiac development
and function. miRNA-1, contributing to ~40% of total
miRNAs in the heart, has been shown to promote
cardiomyocyte proliferation and suppress apoptosis during
development; however, its function in cardiac reprogram-
ming remains unknown [33]. miRNA-133 is important
in orchestrating cardiac development, gene expression,
growth, and function [34]. It also promotes cardiomyocyte
proliferation by repressing the transcriptional regulator
SNAI1 and silences fibroblast gene signatures during
reprogramming [35]. These two miRNAs have been used
in combination with other factors to successfully enhance
cardiac reprogramming. A novel approach was reported
recently where a combination of miRNAs promoted direct
conversion of cardiac fibroblasts into cardiomyocyte-like
cells without the need for forced expression of exogenous
TFs. A combination of miRNA-1, miRNA-133, miRNA-
208, and miRNA-499 was reported to be sufficient to convert
mouse cardiac fibroblasts into iCMs without the addition
of other factors in vivo [36]. The potential mechanism
for this effect is thought to be due to altered H3K27
methyltransferase and demethylase expression, which leads
to changes in the epigenetic landscape of fibroblasts to
induce their conversion into cardiomyocyte-like cells. A
10-fold increase in miRNA-mediated murine cardiac
fibroblast reprogramming was observed when miRNA-1,
miRNA-133, miRNA-208, and miRNA-499 were combined
with JAK inhibitor I [30].
Similarly, when miRNA-133 was used in conjunction
with GMT, Mesp1, and Myocd or GHT, Myocd, and
miRNA-1, the reprogramming efficiency was increased in
both human and mouse fibroblasts by repressing Snai1 and
silencing fibroblast gene signatures [35, 37]. Zhao et al. used
a combination of GMHT, miRNA-1, miRNA-133, miRNA-
208, miRNA-499, Y-27632, and A83-01 in MEFs and mouse
adult fibroblasts to achieve ~60% cardiac troponin T+ and
60% α-actinin+ iCMs [29]. miRNA-590, a miRNA that can
induce adult cardiomyocyte proliferation, was recently
shown to be able to replace HAND2 and MYOCD in GMT
direct reprogramming experiments using human and por-
cine fibroblasts [38, 39]. While GMT was initially shown to
be sufficient for cardiac reprogramming, further studies have
indicated that a multiprong approach may be necessary to
enhance reprogramming and could hold great promise for
future in vivo clinical application.
Long noncoding RNAs (lncRNAs) are a heteroge-
neous group of transcripts longer than 200 nucleotides
that exert major regulatory roles in gene expression
during development and disease through many different
mechanisms. Recent advances in sequencing and analysis
technologies have allowed many lncRNAs to be identified,
but due to their complex and multiple mechanisms of
action as well as to the low interspecies conservation, it
훼MHC-GFP
ACTA1
DAPI
(a) (b)
Figure 1: GMT+A83-01 reprogramming in MEFs. (a) Immunocytochemistry for the cardiac markers αMHC-GFP and α-actinin (ACTA1).
(b) Video snapshot showing beating areas of reprogrammed cells (outlined areas).
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has been difficult to decipher biological functions of
many lncRNAs [40]. A list of cardiac lncRNAs that are
involved in cardiac differentiation, development, and
contractile function has been reviewed [41]. Braveheart
(Bvht) and Fendrr play a critical role in cardiac lineage
commitment by regulating the transition from mesoderm
to CPCs through activation of key cardiac development genes
and TFs including some of those studied above [42–44].
Hotair, Chaer, and other lncRNAs have also been shown to
regulate the epigenetic landscape in cardiac development
by regulating proteins involved in histone modification at
targeted promoters [45, 46]. lncRNAs play an extensive
role in the regulation of cardiac development and gene
expression; therefore, it may be advantageous to explore
the use of lncRNAs in direct reprogramming studies; how-
ever, no direct reprogramming studies have been published
using lncRNAs.
3.3. Epigenetic Modifiers. Reprogramming of one somatic cell
type to another requires the activation and repression of
multiple sets of genes, leading to vast genomic changes. The
epigenetic landscape plays an important role in determining
the reprogramming efficiency as accessibility of TFs to their
DNA targets is critical. During reprogramming, epigenetic
marks such as histone methylation, acetylation, and ubiquiti-
nation must be added and removed from fibroblast- and
cardiac-specific genes. These modifications will suppress
expression of fibroblast genes while activating cardiac genes
by remodeling chromatin structure to allow or restrict the
access of TFs to their target genes. It has been shown that
during cardiac direct reprogramming, the trimethylated
histone H3 of lysine 27 (H3K27me3), which marks inactive
chromatin, increases at fibroblast promoters and decreases
at cardiac promoters while the activated chromatin mark
H3K4me3 shows the opposite pattern at important loci
[11, 47]. Moreover, the activating H3K4me2 histone mark
has been shown to be increased at the regulatory regions
of miRNA-1 and miRNA-133 [29]. To this end, attempts
to improve direct cardiac reprogramming have been
carried out using modulators of epigenetic marks. Bmi1
was identified as a barrier to reprogramming by modifying
histone marks at key cardiogenic loci, thus inhibiting iCM
induction. When Bmi1 activity was knocked down, the
active histone mark, H3K4me3, was increased while the
repressive H2AK119ub mark was reduced, leading to
increased cardiac gene expression at important loci [48].
In nonintegrative and in vivo reprogramming experiments
discussed later in this review, other epigenetic modifiers
that inhibit histone methyl transferases and histone
demethylase have been used. The importance of epigenetic
landscape and changes that happen during reprogramming
have recently begun to be unraveled using a single-cell
transcriptomic approach by Liu et al. [49]. These results
highlight the complexity of the reprogramming process
and the importance of the influence of a variety of factors,
warranting additional research into the sequential addition
of TFs, noncoding RNAs, cytokines, inhibitors, and epige-
netic modifiers to further improve the reprogramming
efficiency.
4. Direct Reprogramming to Expandable
Cardiac Progenitor Cells
Another recent approach of clinical promise is the generation
of expandable CPCs by direct reprogramming. The goal of
this approach is to safely create CPCs in vitro that can then
be expanded in culture before transplantation into the
injured heart. Upon transplantation, the CPCs will differ-
entiate into three major cells of the heart; cardiomyocytes,
endothelial cells, and smooth muscle cells. Two groups
were able to successfully generate expandable CPCs using
unique reprogramming cocktails containing a variety of
biomolecules described above. Lalit et al. generated CPCs
from fibroblasts using Mesp1, Tbx5, Gata4, Nkx2–5, and
Baf60c, a chromatin remodeling protein. In vitro expan-
sion and maintenance of a CPC state were achieved using
a Wnt activator, BIO, and a JAK/STAT activator, LIF
[50, 51]. On the other hand, Zhang et al. used a chemical
approach to reprogramming fibroblasts to CPCs. Genera-
tion, expansion, and maintenance of CPCs were achieved
by the addition of BMP4, activin A, CHIR99021, and
SU504 (a FGF, VEGF, and PDGF signaling inhibitor)
[52]. Both groups were able to show that their repro-
grammed CPCs maintained their characteristics for many
passages in culture and could generate cardiomyocytes,
endothelial cells, and smooth muscle cells both in vitro
and in vivo when transplanted. Direct reprogramming of
fibroblasts to CPCs represents a scalable method for the
generation of multiple cardiac cell types for clinical applica-
tions; however, this approach has not yet been applied to
human cells.
5. Progress of In Vivo Direct Reprogramming
The ultimate goal of direct reprogramming is to be able
to repair the damaged myocardium after injury. Direct
reprogramming offers two potential approaches for heart
regeneration: (1) transplantation of reprogrammed fibro-
blasts into the infarcted heart and (2) reprogramming
resident cardiac fibroblasts directly to cardiomyocytes.
The first attempt at cardiac regeneration using direct
reprogramming was carried out using cardiac fibroblasts
that were transduced with GMT for 1 day and then
transplanted into mouse hearts [11]. Analysis of these
cells posttransplantation revealed that they successfully
generated cardiomyocyte-like cells in vivo. Other studies
have used in vivo transplantation of reprogrammed cells
to test their regenerative potential. However, cell trans-
plantation is complicated by many factors such as cell
retention, viability, structural and functional integration,
and immune rejection. Therefore, in situ repair of the
heart is best studied by targeting endogenous cardiac
fibroblasts through viral transfection of the infarct zone.
This approach was attempted in 2012 by Song et al.
and Qian et al., in which local delivery of GM(H)T
viruses induced reprogramming of nonmyocytes into
iCMs by 4 weeks postsurgery [53, 54]. Additionally, Qian
et al. reported that codelivery of thymosin β4 and GMT
viruses further improved ejection fraction and reduced scar
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formation. Interestingly, it has been reported that the
in vivo cardiac niche may improve the efficiency of repro-
gramming; however, the mechanisms underlying this
observation remain elusive [27, 36, 53, 54]. Several studies
have improved the in vivo reprogramming efficiency even
further by optimizing polycistronic expression vectors to
control the stoichiometry of TF expression or by the addi-
tion of small molecules delivered with TFs [27, 55–57].
6. Are All Fibroblasts Created Equal?
Cardiac fibroblasts are ideal targets for direct reprogram-
ming as they are the most prominent cell type within
the heart and play key roles in regulating normal myocar-
dial function as well as adverse remodeling following
injury. Various mouse and/or human fibroblast sources
have been tested, including mouse embryonic fibroblasts,
tail-tip fibroblasts, and dermal fibroblasts, with varying
results, suggesting the importance of the starting cell type
for direct reprogramming. It is also interesting to note that
in vivo reprogramming has been reported to be more
efficient than in vitro reprogramming, despite the fact that
upon injury, cardiac fibroblast expresses TGF-β, which has
been shown to be inhibitory to reprogramming in vitro.
Furthermore, our lab has shown that cardiac fibroblasts
are a heterogeneous population from different embryonic
origins [58]. It is possible to postulate that perhaps a sub-
population of cardiac fibroblasts may be more susceptible
to reprogramming depending on their developmental ori-
gin. Further understanding of the epigenetic landscape of
fibroblasts and their susceptibility to direct reprogramming
would be of great use to the field. This would also open
up the possibility for repairing the heart by targeting
specific fibroblast populations.
7. Nonintegrative Methods of Direct
Reprogramming for Future In vivo
Applications
The reprogramming results shown thus far suggest that
direct reprogramming of fibroblasts can be a feasible
therapeutic approach to repairing the injured myocardium.
However, relatively safe methods for the delivery of vari-
ous reprogramming factors need to be explored for
in vivo applications. Adeno-associated virus (AAV) vectors
are attractive tools for TF delivery, but the limited capacity
of about 4.5 kb complicates the expression of multiple TFs
in a single vector and still involves the use of an integra-
tive viral system. Sendai virus reprogramming is an
appealing alternative to AAV since it does not integrate
into the host genome and has been successfully used to
reprogram many different cell types to pluripotency; how-
ever, its use in direct reprogramming has not yet been
explored. A recent study showed that acute expression
of GMT in nonintegrating adenoviral vectors was as effi-
cient as lentiviral vectors at reprogramming in a rat
infarct model, which has increased the clinical applicabil-
ity of in vivo reprogramming. As described in two recent
reports, the temporal control and stoichiometric control of
TFs are also important in determining reprogramming effi-
ciency [57, 59]. Unfortunately, current in vivo viral repro-
gramming tools are unable to control dosage and temporal
expression of TFs but warrant further investigation to
improve reprogramming efficiency.
Compared to TFs and miRNAs, small molecules have
many advantages such as more effective cell delivery and
being nonimmunogenic and less expensive and are gener-
ally safer. Moreover, it is more convenient to control the
process of reprogramming through varying small molecule
concentrations and combinations in vitro. A combination
of ascorbic acid, RepSox (a TGF-β inhibitor), forskolin,
valproic acid, and CHIR99021 (a WNT pathway activator
through the inhibition of glycogen synthase kinase 3) was
shown to reprogram MEFs and mouse tail-tip fibroblasts
to iCMs in vitro [60]. Cao et al. were able to use a cocktail
of 9 small molecules (CHIR99021, A83-01, BIX01294,
AS8351, SC1, OAC2, Y27632, SU16F, and JNJ10198409)
to direct cardiac reprogramming of human foreskin fibro-
blasts in vitro before transplantation in injured murine
hearts [61]. Among these small molecules were the epige-
netic modifiers BIX01294 (a methyltransferase inhibitor)
and AS8351 (a histone demethylase inhibitor), SC1 (an
ERK2 and Ras-GAP inhibitor), OAC2 (an Oct4 activator),
SU16F (a PDGFRβ inhibitor), and JNJ10198409 (a PDGF
receptor tyrosine kinase inhibitor). However, the use of small
molecules for in vivo reprogramming poses some unan-
swered questions. Small molecules can enter the blood
stream and spread to other organs with unknown conse-
quences. Additionally, the ability of timely uptake into
specific target cell type remains a challenge. Development
of novel biomaterials for local delivery, controlled release,
and retention of small molecules is still needed.
Another promising nonviral method of direct cardiac
reprogramming is the use of modified mRNAs (mod-
RNAs) [62]. ModRNAs are noncytopathic and do not
integrate into the host genome, thus offering a safer
approach to reprogramming. ModRNAs have been used
successfully to generate induced pluripotent stem cells
from somatic cells through transient expression of
mRNAs that direct cell fate. ModRNAs are produced
using an in vitro transcription system to generate mRNAs
that contain a synthetic 5′ guanine cap and poly-A tail,
which improves half-life and stability, as well as modified
nucleotide bases that reduce the innate immune response
of the host cell. This technology is endowed with a
number of attractive properties that would make it a
potentially powerful platform for direct cardiac repro-
gramming. ModRNAs can mediate robust and dose-
titratable expression of key TFs over a specified time
and in a particular sequence. Previous studies outlined
in this review have highlighted the fact that direct cardiac
reprogramming is a complex process that may require
sequential treatments to better overcome the reprogramming
barrier. ModRNAs may be ideal for direct reprogramming
as they have a relatively short half-life; therefore, distinct
factors can be expressed for a short period of time and
then removed from the reprogramming cocktail or added
again to continue expression. ModRNAs may open the
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door to following a more developmentally relevant
sequence of TFs to improve transcription. It is also foresee-
able that modRNAs could be combined with other small
molecules, cytokines, and noncoding RNAs discussed in
this review.
8. Roadblocks and Challenges
There has been significant progress in recent years with
direct cardiac reprogramming through important discov-
eries in understanding the mechanism of reprogramming
and the biology of cardiac development. However, several
challenges must be addressed prior to clinical translation
of this technology. The reprogramming efficiency must
be increased in order to generate enough cells in vitro
for transplantation. One avenue that has the potential to
generate the number of cells needed for transplantation
is reprogramming to CPCs, which can be expanded
in vitro before transplantation. The retention, integration,
and maturation of iCMs or CPCs after transplantation
remain a concern. Multiplex immunostaining and patch
clamp analysis have also revealed the presence of all three
cardiomyocyte types (atrial, ventricular, and pacemaker)
in iCMs, therefore increasing the risk of arrhythmias
[16]. There is a need to develop techniques to generate
specific subtypes of cardiomyocytes for both in vitro
and in vivo direct reprogramming. A safe and effective
approach to delivering and targeting reprogramming
factors in vivo will be needed to circumvent in vitro
reprogramming completely.
Transcription factors, inhibitors, cytokines, noncoding
RNAs, and epigenetic modulators have been shown to be
important for direct cardiac reprogramming. However,
studies have uncovered variable reproducibility between
different labs, leading to wide differences in reprogram-
ming efficiency, maturity, and characteristics of the iCMs.
These inconsistencies can be attributed to many factors
other than the reprogramming factors themselves. First,
the components of culture media used during reprogram-
ming widely vary from group to group along with the
duration of reprogramming before analysis. Additionally,
the induction time, the type of fibroblasts, and the amount
and sequence of factors used along with the time exposed
to reprogramming factors are different between protocols.
Moreover, the criteria used to measure the outcome and
success are inconsistent and not standardized in the field.
Reprogramming success is measured by some as the
presence of cardiac-related structural proteins on immuno-
staining, while others employ a much more detailed
approach including appearance of spontaneous beating
along with gene and protein expression data. Even differ-
ences in the cardiac markers used to analyze the reprogram-
ming efficiency, cardiac troponin T (cTnT) versus alpha
myosin heavy chain (αMHC) versus GCaMP activity, and
the method of measurement, flow cytometry versus immu-
nofluorescence (IF), make comparisons among studies
difficult. A myriad of criteria and stringency that have
been used to evaluate reprogramming efficiency have been
summarized by Addis and Epstein and are presented in
Table 3 [63].
Optimization of the minimal yet sufficient combination
of factors to improve reprogramming requires further
research. Studies presented here have revealed that simply
expressing a few core transcription factors is not sufficient
for efficient cardiac reprogramming [64]. There may also be
a dosage and temporal requirement for reprogramming fac-
tors [57, 59]. Other factors such as activated cellular signaling
processes and epigenetic landscape should be considered to
improve efficiency and quality. For example, when the
TGF-β signaling pathway was disrupted by small molecules
or when important cardiac regulatory miRNAs were added,
an increase in reprogramming was observed, supporting the
hypothesis that a multifaceted approach is likely necessary
to achieve high reprogramming efficiency. Furthermore,
these studies highlight the significant differences between
mouse and human reprogramming as well as the effect of
the starting fibroblast type (MEFs, tail-tip fibroblasts, or
cardiac fibroblasts). Differences in fibroblast populations
may be attributed to differences in epigenetic landscape,
which can be influenced by many factors such as the cell
environment or developmental origin. Further research on
the heterogeneity of fibroblast epigenetic landscapes is war-
ranted and will be of great benefit to direct reprogramming.
9. Conclusion
In this review, we discussed the reprogramming of fibroblasts
into cardiomyocyte-like cells and expandable CPCs using
Table 3: Criteria to evaluate reprogramming efficiency. Adapted
from Addis and Epstein [63].
Characteristic Stringency Assay technique(s)
Gene expression Low
RT-qPCR
Reporter transgene
Protein expression Low
Immunostaining
Flow cytometry
Western blot
Transcriptome and
epigenetic analysis
High
Microarray
RNA-seq
ChIP-seq
ATAC-seq
Contraction and
force generation
High
Spontaneous
Chemical stimulation
Electrical stimulation
Three-dimensional
bioengineered platforms
Electrophysiological High
Patch clamp
Microelectrode arrays
Optical mapping
Calcium transients
and
electrical coupling
High
Calcium-sensitive dyes
Genetically encoded indicators
(GCaMP)
Optical mapping
Functional
improvement
High Echocardiography
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transcription factors, small molecules, noncoding RNAs,
and other biologics for the treatment of heart failure
(Figure 2). Despite the current limitations that exist with
direct cardiac reprogramming, this technology offers great
promise for cardiac regeneration therapy. It is clear that
the reprogramming process is very complex and that
many factors have profound influence over this process.
Continued research of key transcription factors, noncoding
RNAs, small molecules, reprogramming mechanisms,
delivery and targeting methods, and biomaterials will help
advance direct cardiac reprogramming to large animal
models and ultimately for the treatment of heart failure.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Acknowledgments
The authors would like to thank Sara Ranjbarvaziri for her
help in figure preparation and Ngoc B. Nguyen for critically
reading this review. This work was supported in part by
grants from the National Institutes of Health (NIH) (DP2
HL127728) and the California Institute for Regenerative
Medicine (CIRM) (RN3-06378).
References
[1] E. Braunwald, “The war against heart failure: the Lancet
lecture,” The Lancet, vol. 385, no. 9970, pp. 812–824, 2015.
[2] P. A. Heidenreich, N. M. Albert, L. A. Allen et al., “American
Heart Association Advocacy Coordinating Committee,
Council on Arteriosclerosis, Thrombosis and Vascular Biol-
ogy, Council on Cardiovascular Radiology and Intervention,
Council on Clinical Cardiology, Council on Epidemiology
and Prevention, Stroke Council. Forecasting the impact of
heart failure in the United States: a policy statement from the
American Heart Association,” Circulation: Heart Failure,
vol. 6, no. 3, pp. 606–619, 2013.
[3] T. J. Cahill, R. P. Choudhury, and P. R. Riley, “Heart regener-
ation and repair after myocardial infarction: translational
opportunities for novel therapeutics,” Nature Reviews Drug
Discovery, vol. 16, no. 10, pp. 699–717, 2017.
[4] C. J. Taylor, A. K. Roalfe, R. Iles, and F. D. Hobbs, “Ten-year
prognosis of heart failure in the community: follow-up data
from the Echocardiographic Heart of England Screening
(ECHOES) study,” European Journal of Heart Failure,
vol. 14, no. 2, pp. 176–184, 2012.
[5] R. L. Davis, H. Weintraub, and A. B. Lassar, “Expression of a
single transfected cDNA converts fibroblasts to myoblasts,”
Cell, vol. 51, no. 6, pp. 987–1000, 1987.
[6] J. Choi, M. L. Costa, C. S. Mermelstein, C. Chagas, S. Holtzer,
and H. Holtzer, “MyoD converts primary dermal fibroblasts,
chondroblasts, smooth muscle, and retinal pigmented epithe-
lial cells into striated mononucleated myoblasts and multinu-
cleated myotubes,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 87, no. 20,
pp. 7988–7992, 1990.
[7] T. Vierbuchen, A. Ostermeier, Z. P. Pang, Y. Kokubu, T. C.
Südhof, and M. Wernig, “Direct conversion of fibroblasts to
functional neurons by defined factors,” Nature, vol. 463,
no. 7284, pp. 1035–1041, 2010.
[8] B. Yu, Z. Y. He, P. You et al., “Reprogramming fibroblasts into
bipotential hepatic stem cells by defined factors,” Cell Stem
Cell, vol. 13, no. 3, pp. 328–340, 2013.
In vitro
Fibroblasts
Transcription factors
MicroRNAs
Transcription factors
MicroRNAs
Small molecules
Cell transplantation
D
irect reprogram
m
ing
VEGF
Cytokines
FGF2
FGF10
TGF훽
Notch
Wnt
Expansion
CPCs
iCMs
In vivo
Biomolecule injection
In situ reprogramming of
fibroblasts toward
cardiomycytes
Epigenetic modifiers
Sca
r ti
ssu
e
Inhibitors
Figure 2: Schematic showing the current and future applications of direct cardiac reprogramming.
8 Stem Cells International
[9] P. Huang, Z. He, S. Ji et al., “Induction of functional
hepatocyte-like cells from mouse fibroblasts by defined
factors,” Nature, vol. 475, no. 7356, pp. 386–389, 2011.
[10] H. Xie, M. Ye, R. Feng, and T. Graf, “Stepwise reprogramming
of B cells into macrophages,” Cell, vol. 117, no. 5, pp. 663–676,
2004.
[11] M. Ieda, J. D. Fu, P. Delgado-Olguin et al., “Direct reprogram-
ming of fibroblasts into functional cardiomyocytes by defined
factors,” Cell, vol. 142, no. 3, pp. 375–386, 2010.
[12] Y. Hiroi, S. Kudoh, K. Monzen et al., “Tbx5 associates with
Nkx2-5 and synergistically promotes cardiomyocyte differen-
tiation,” Nature Genetics, vol. 28, no. 3, pp. 276–280, 2001.
[13] C. Perrino and H. A. Rockman, “GATA4 and the two sides
of gene expression reprogramming,” Circulation Research,
vol. 98, no. 6, pp. 715-716, 2006.
[14] E. Dodou, M. P. Verzi, J. P. Anderson, S. M. Xu, and B. L.
Black, “Mef2c is a direct transcriptional target of ISL1 and
GATA factors in the anterior heart field during mouse
embryonic development,” Development, vol. 131, no. 16,
pp. 3931–3942, 2004.
[15] Y. S. Dai, P. Cserjesi, B. E. Markham, and J. D. Molkentin,
“The transcription factors GATA4 and dHAND physically
interact to synergistically activate cardiac gene expression
through a p300-dependent mechanism,” Journal of Biological
Chemistry, vol. 277, no. 27, pp. 24390–24398, 2002.
[16] Y. J. Nam, C. Lubczyk, M. Bhakta et al., “Induction of diverse
cardiac cell types by reprogramming fibroblasts with cardiac
transcription factors,” Development, vol. 141, no. 22,
pp. 4267–4278, 2014.
[17] H. Hirai, N. Katoku-Kikyo, S. A. Keirstead, and N. Kikyo,
“Accelerated direct reprogramming of fibroblasts into
cardiomyocyte-like cells with the MyoD transactivation
domain,” Cardiovascular Research, vol. 100, no. 1, pp. 105–
113, 2013.
[18] R. C. Addis, J. L. Ifkovits, F. Pinto et al., “Optimization of direct
fibroblast reprogramming to cardiomyocytes using calcium
activity as a functional measure of success,” Journal of Molec-
ular and Cellular Cardiology, vol. 60, pp. 97–106, 2013.
[19] S. Protze, S. Khattak, C. Poulet, D. Lindemann, E. M. Tanaka,
andU. Ravens, “Anew approach to transcription factor screen-
ing for reprogramming of fibroblasts to cardiomyocyte-like
cells,” Journal of Molecular and Cellular Cardiology, vol. 53,
no. 3, pp. 323–332, 2012.
[20] N. Christoforou, M. Chellappan, A. F. Adler et al., “Transcrip-
tion factors MYOCD, SRF, Mesp1 and SMARCD3 enhance
the cardio-inducing effect of GATA4, TBX5, and MEF2C
during direct cellular reprogramming,” PLoS One, vol. 8,
no. 5, article e63577, 2013.
[21] J. F. Islas, Y. Liu, K. C.Weng et al., “Transcription factors ETS2
and MESP1 transdifferentiate human dermal fibroblasts into
cardiac progenitors,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 109, no. 32,
pp. 13016–13021, 2012.
[22] R. Wada, N. Muraoka, K. Inagawa et al., “Induction of
human cardiomyocyte-like cells from fibroblasts by defined
factors,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 110, no. 31,
pp. 12667–12672, 2013.
[23] J. D. Fu, N. R. Stone, L. Liu et al., “Direct reprogramming of
human fibroblasts toward a cardiomyocyte-like state,” Stem
Cell Reports, vol. 1, no. 3, pp. 235–247, 2013.
[24] A. Ao, J. Hao, C. R. Hopkins, and C. C. Hong, “DMH1, a novel
BMP small molecule inhibitor, increases cardiomyocyte
progenitors and promotes cardiac differentiation in mouse
embryonic stem cells,” PLoS One, vol. 7, no. 7, article e41627,
2012.
[25] W. Cai, R. M. Guzzo, K. Wei, E. Willems, H. Davidovics, and
M. Mercola, “A nodal-to-TGFβ cascade exerts biphasic
control over cardiopoiesis,” Circulation Research, vol. 111,
no. 7, pp. 876–881, 2012.
[26] J. L. Ifkovits, R. C. Addis, J. A. Epstein, and J. D. Gearhart,
“Inhibition of TGFβ signaling increases direct conversion of
fibroblasts to induced cardiomyocytes,” PLoS One, vol. 9,
no. 2, article e89678, 2014.
[27] T. M. Mohamed, N. R. Stone, E. C. Berry et al., “Chemical
enhancement of in vitro and in vivo direct cardiac reprogram-
ming,” Circulation, vol. 135, no. 10, pp. 978–995, 2017.
[28] M. Abad, H. Hashimoto, H. Zhou et al., “Notch inhibition
enhances cardiac reprogramming by increasing MEF2C
transcriptional activity,” Stem Cell Reports, vol. 8, no. 3,
pp. 548–560, 2017.
[29] Y. Zhao, P. Londono, Y. Cao et al., “High-efficiency
reprogramming of fibroblasts into cardiomyocytes requires
suppression of pro-fibrotic signalling,” Nature Communica-
tions, vol. 6, p. 8243, 2015.
[30] T. M. Jayawardena, B. Egemnazarov, E. A. Finch et al., “Micro-
RNA-mediated in vitro and in vivo direct reprogramming of
cardiac fibroblasts to cardiomyocytes,” Circulation Research,
vol. 110, no. 11, pp. 1465–1473, 2012.
[31] H. Zhou, M. E. Dickson, M. S. Kim, R. Bassel-Duby, and
E. N. Olson, “Akt1/protein kinase B enhances transcriptional
reprogramming of fibroblasts to functional cardiomyocytes,”
Proceedings of the National Academy of Sciences of the
United States of America, vol. 112, no. 38, pp. 11864–
11869, 2015.
[32] H. Yamakawa, N. Muraoka, K. Miyamoto et al., “Fibroblast
growth factors and vascular endothelial growth factor promote
cardiac reprogramming under defined conditions,” Stem Cell
Reports, vol. 5, no. 6, pp. 1128–1142, 2015.
[33] P. K. Rao, Y. Toyama, H. R. Chiang et al., “Loss of cardiac
microRNA-mediated regulation leads to dilated cardiomyopa-
thy and heart failure,” Circulation Research, vol. 105, no. 6,
pp. 585–594, 2009.
[34] N. Liu, S. Bezprozvannaya, A. H. Williams et al., “MicroRNA-
133a regulates cardiomyocyte proliferation and suppresses
smooth muscle gene expression in the heart,” Genes &
Development, vol. 22, no. 23, pp. 3242–3254, 2008.
[35] N. Muraoka, H. Yamakawa, K. Miyamoto et al., “MiR-133
promotes cardiac reprogramming by directly repressing
Snai1 and silencing fibroblast signatures,” The EMBO Journal,
vol. 33, no. 14, pp. 1565–1581, 2014.
[36] T. M. Jayawardena, E. A. Finch, L. Zhang et al., “MicroRNA
induced cardiac reprogramming in vivo: evidence for mature
cardiac myocytes and improved cardiac function,” Circulation
Research, vol. 116, no. 3, pp. 418–424, 2015.
[37] Y. J. Nam, K. Song, X. Luo et al., “Reprogramming of human
fibroblasts toward a cardiac fate,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 110,
no. 14, pp. 5588–5593, 2013.
[38] A. Eulalio, M. Mano, M. D. Ferro et al., “Functional screening
identifies miRNAs inducing cardiac regeneration,” Nature,
vol. 492, no. 7429, pp. 376–381, 2012.
9Stem Cells International
[39] V. P. Singh, M. Mathison, V. Patel et al., “MiR-590 promotes
transdifferentiation of porcine and human fibroblasts toward
a cardiomyocyte-like fate by directly repressing specificity
protein 1,” Journal of the American Heart Association, vol. 5,
no. 11, article e003922, 2016.
[40] P. Johnsson, L. Lipovich, D. Grandér, and K. V. Morris,
“Evolutionary conservation of long non-coding RNAs;
sequence, structure, function,” Biochimica et Biophysica Acta
(BBA) - General Subjects, vol. 1840, no. 3, pp. 1063–1071,
2014.
[41] C. P. C. Gomes, H. Spencer, K. L. Ford et al., “The function and
therapeutic potential of long non-coding RNAs in cardiovas-
cular development and disease,” Molecular Theraphy Nucleic
Acids, vol. 8, pp. 494–507, 2017.
[42] C. A. Klattenhoff, J. C. Scheuermann, L. E. Surface et al.,
“Braveheart, a long noncoding RNA required for cardiovascu-
lar lineage commitment,” Cell, vol. 152, no. 3, pp. 570–583,
2013.
[43] Z. Xue, S. Hennelly, B. Doyle et al., “A G-rich motif in the
lncRNA Braveheart interacts with a zinc-finger transcription
factor to specify the cardiovascular lineage,” Molecular Cell,
vol. 64, no. 1, pp. 37–50, 2016.
[44] P. Grote, L. Wittler, D. Hendrix et al., “The tissue-specific
lncRNA Fendrr is an essential regulator of heart and body wall
development in the mouse,” Developmental Cell, vol. 24, no. 2,
pp. 206–214, 2013.
[45] Z. Wang, X. J. Zhang, Y. X. Ji et al., “The long noncoding
RNA Chaer defines an epigenetic checkpoint in cardiac
hypertrophy,” Nature Medicine, vol. 22, no. 10, pp. 1131–
1139, 2016.
[46] Z. Wang and Y. Wang, “Dawn of the epi-LncRNAs: new
path from Myheart,” Circulation Research, vol. 116, no. 2,
pp. 235-236, 2015.
[47] Z. Liu, O. Chen, M. Zheng et al., “Re-patterning of H3K27me3,
H3K4me3 and DNAmethylation during fibroblast conversion
into induced cardiomyocytes,” Stem Cell Research, vol. 16,
no. 2, pp. 507–518, 2016.
[48] Y. Zhou, L. Wang, H. R. Vaseghi et al., “Bmi1 is a key
epigenetic barrier to direct cardiac reprogramming,” Cell Stem
Cell, vol. 18, no. 3, pp. 382–395, 2016.
[49] Z. Liu, L. Wang, J. D. Welch et al., “Single-cell transcriptomics
reconstructs fate conversion from fibroblast to cardiomyo-
cyte,” Nature, vol. 551, no. 7678, pp. 100–104, 2017.
[50] P. A. Lalit, M. R. Salick, D. O. Nelson et al., “Lineage
reprogramming of fibroblasts into proliferative induced
cardiac progenitor cells by defined factors,” Cell Stem Cell,
vol. 18, no. 3, pp. 354–367, 2016.
[51] P. A. Lalit, A. M. Rodriguez, K. M. Downs, and T. J. Kamp,
“Generation of multipotent induced cardiac progenitor cells
from mouse fibroblasts and potency testing in ex vivo mouse
embryos,” Nature Protocols, vol. 12, no. 5, pp. 1029–1054,
2017.
[52] Y. Zhang, N. Cao, Y. Huang et al., “Expandable cardiovascular
progenitor cells reprogrammed from fibroblasts,” Cell Stem
Cell, vol. 18, no. 3, pp. 368–381, 2016.
[53] K. Song, Y. J. Nam, X. Luo et al., “Heart repair by reprogram-
ming non-myocytes with cardiac transcription factors,”
Nature, vol. 485, no. 7400, pp. 599–604, 2012.
[54] L. Qian, Y. Huang, C. I. Spencer et al., “In vivo reprogramming
of murine cardiac fibroblasts into induced cardiomyocytes,”
Nature, vol. 485, no. 7400, pp. 593–598, 2012.
[55] H. Ma, L. Wang, C. Yin, J. Liu, and L. Qian, “In vivo cardiac
reprogramming using an optimal single polycistronic
construct,” Cardiovascular Research, vol. 108, no. 2, pp. 217–
219, 2015.
[56] M. Mathison, V. P. Singh, R. P. Gersch et al., ““Triplet”
polycistronic vectors encoding Gata4, Mef2c, and Tbx5
enhances postinfarct ventricular functional improvement
compared with singlet vectors,” The Journal of Thoracic and
Cardiovascular Surgery, vol. 148, no. 4, pp. 1656–1664.e2,
2014.
[57] L. Wang, Z. Liu, C. Yin et al., “Stoichiometry of Gata4, Mef2c,
and Tbx5 influences the efficiency and quality of induced
cardiac myocyte reprogramming,” Circulation Research,
vol. 116, no. 2, pp. 237–244, 2015.
[58] S. R. Ali, S. Ranjbarvaziri, M. Talkhabi et al., “Developmental
heterogeneity of cardiac fibroblasts does not predict patholog-
ical proliferation and activation,” Circulation Research,
vol. 115, no. 7, pp. 625–635, 2014.
[59] T. C. Umei, H. Yamakawa, N. Muraoka et al., “Single-
construct polycistronic doxycycline-inducible vectors improve
direct cardiac reprogramming and can be used to identify the
critical timing of transgene expression,” International Journal
of Molecular Sciences, vol. 18, no. 8, 2017.
[60] Y. Fu, C. Huang, X. Xu et al., “Direct reprogramming of mouse
fibroblasts into cardiomyocytes with chemical cocktails,” Cell
Research, vol. 25, no. 9, pp. 1013–1024, 2015.
[61] N. Cao, Y. Huang, J. Zheng et al., “Conversion of human
fibroblasts into functional cardiomyocytes by small mole-
cules,” Science, vol. 352, no. 6290, pp. 1216–1220, 2016.
[62] L. Warren, P. D. Manos, T. Ahfeldt et al., “Highly efficient
reprogramming to pluripotency and directed differentiation
of human cells with synthetic modified mRNA,” Cell Stem Cell,
vol. 7, no. 5, pp. 618–630, 2010.
[63] R. C. Addis and J. A. Epstein, “Induced regeneration–the
progress and promise of direct reprogramming for heart
repair,” Nature Medicine, vol. 19, no. 7, pp. 829–836, 2013.
[64] J. X. Chen, M. Krane, M. A. Deutsch et al., “Inefficient
reprogramming of fibroblasts into cardiomyocytes using
Gata4, Mef2c, and Tbx5,” Circulation Research, vol. 111,
no. 1, pp. 50–55, 2012.
10 Stem Cells International
